Purpose: To demonstrate the clinical value of a non-Gaussian diffusion model using fractional order calculus (FROC) for early prediction of the response of gastrointestinal stromal tumor to second-line sunitinib targeted therapy. Methods: Fifteen patients underwent sunitinib treatment after imatinib resistance. Diffusion-weighted imaging with multiple b-values was performed before treatment (baseline) and 2 weeks (for early prediction of response) after initiating sunitinib treatment. Conventional MRI images at 12 weeks were used to determine the good and poor responders according to the modified Choi criteria for MRI. Diffusion coefficient D, fractional order parameter b (which correlates to intravoxel tissue heterogeneity), and a microstructural quantity m were calculated using the FROC model. The FROC parameters and the longest diameter of the lesion, as well as their changes after 2 weeks of treatment, were compared between the good and poor responders. Additionally, the pretreatment FROC parameters were individually combined with the change in D (DD) using a logistic regression model to evaluate response to sunitinib treatment with a receiver operating characteristic analysis. Results: Forty-two good-responding and 32 poor-responding lesions were identified. Significant differences were detected in pretreatment b (0.67 versus 0.74, P ¼ 0.011) and DD (45.7% versus 12.4%, P ¼ 0.001) between the two groups. The receiver operating characteristic analysis showed that DD had a significantly higher predictive power than the tumor size change (area under the curve: 0.725 versus 0.580; 0.95 confidence interval). When DD was combined with pretreatment b, the area under the curve improved to 0.843 with a predictive accuracy of 75.7% (56 of 74). Conclusions: The non-Gaussian FROC diffusion model showed clinical value in early prediction of gastrointestinal stromal tumor response to second-line sunitinib targeted therapy. The pretreatment FROC parameter b can increase the predictive accuracy when combined with the change in diffusion coefficient during treatment.
INTRODUCTION
Over the past decade, diffusion-weighted imaging (DWI) has been used increasingly in the abdomen, not only for cancer detection and characterization, but also for early evaluation of tumor response to therapies (1) (2) (3) (4) (5) (6) . For instance, a recent study indicates that apparent diffusion coefficient (ADC) can predict responses of gastrointestinal stromal tumor (GIST)-the most common mesenchymal tumor initiated from the gastrointestinal tract (7)-to first-line imatinib targeted therapy as early as 1 week after the initiation of treatment (3) . The good performance of ADC has been attributed to its association with tissue cellularity. Despite the great success of ADC for treatment prediction, ADC is derived from an overly simplified Gaussian diffusion model, which may not adequately capture a wealth of tissue structural and heterogeneity changes as a result of therapy.
In GIST patients who develop resistance to first-line imatinib and are subsequently treated with second-line sunitinib (8) , approximately 40% of patients can develop progressive disease within 3 months (8, 9) . Unlike lesions before first-line imatinib treatment, the progressive GIST lesions to be treated with second-line sunitinib typically exhibit increased and varying degrees of heterogeneity as a consequence of the first-line treatment, resulting in complex tissue structures such as "nodule within a mass" (10, 11) . This tissue heterogeneity prior to sunitinib therapy may provide a new avenue to predicting treatment response in combination with ADC.
Recognizing that information on tissue microstructures or heterogeneity is not directly provided by the prevailing Gaussian diffusion models, several research groups have proposed more sophisticated non-Gaussian diffusion models (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) in an attempt to extract additional tissue structural information. One of these models, known as the fractional order calculus (FROC) model (14, 20) , features a new parameter, fractional order derivative in space b, which has been linked to intravoxel tissue heterogeneity (20, (23) (24) (25) (26) . The goal of this study is to demonstrate the clinical value of the FROC diffusion model for early prediction of the response of GIST to second-line sunitinib targeted therapy.
METHODS

Patients
The institutional review board approved this prospective study, and written informed consent was obtained from all participating patients. The inclusion criteria for patients were (i) unresectable or metastatic GIST confirmed by pathology; (ii) failure of previous imatinib therapy, as confirmed by CT or MRI; (iii) presence of at least one solid lesion larger than 1 cm in diameter or a cystic lesion with wall thickness greater than 1 cm (target lesion); (iv) sunitinib single-drug targeted treatment (50 mg/day, PO); (v) MR examinations at three time points (pretreatment, 2 weeks, and 12 weeks after initiation of sunitinib therapy); and (vi) confirmation of at least one target lesion that could be reliably measured to obtain its longest diameter (LD) and DWI parameters. The exclusion criteria were (i) contraindications for MR examinations, (ii) inadequate number of MR examinations during therapy, (iii) severe complications as a result of targeted agent causing interruption of treatment or dose adjustment, or (iv) excessive image quality degradation on DWI.
Magnetic Resonance Imaging
All enrolled patients underwent overnight fasting to empty the gastrointestinal tract, and were given 20 mg of anisodamine intramuscularly 15 min before the MR examination to inhibit the gastrointestinal motility. Pure water (800-1000 mL) was administered orally to distend the gastrointestinal wall for those lesions located at the stomach.
All MR examinations were performed on a 3T MRI scanner (Discovery MR750, General Electric Healthcare, Milwaukee, WI) with an eight-channel phased-array coil. An abdominal T 2 -weighted single-shot fast spin echo sequence (repetition time (TR)/echo time (TE) ¼ 3000/90 ms; matrix size ¼ 384 Â 256; and field of view (FOV) ¼ 360-400 mm) was applied in a coronal plane to locate the target lesions with a coverage from the top of the diaphragm to the pelvic floor. Based on the coronal images, axial scans covering the target lesions were carried out using a breath-hold T 1 -weighted dual-echo fast spoiled gradient-recalled echo sequence (TR ¼ 200 ms; TE ¼ 1.2 ms for out of phase and 2.3 ms for in phase; flip angle ¼ 85 ; matrix size ¼ 320 Â 160; average ¼ 1) and a respiratory-triggered T 2 -weighted fast recovery fast spin echo sequence (TR ¼ 2 respiratory intervals; TE ¼ 85 ms; matrix size ¼ 320 Â 224; average ¼ 2). The slice thickness and interslice gap in all sequences were 5 and 1 mm, respectively.
To apply the FROC model, a set of axial diffusion MR images was acquired using a single-shot spin-echo echoplanar imaging sequence with 11 b-values (b ¼ 0 1 , 20 1 , 50 1 , 100 1 , 300 2 , 500 2 , 800 2 , 1000 4 , 1500 4 , 2000 6 , and 3000 8 s/ mm 2 , where the subscript denotes the number of signal averages for the corresponding b-value). At each b-value, a Stejskal-Tanner diffusion gradient was successively applied along the x-, y-, and z-axis to obtain a trace-weighted image, to minimize the influence of diffusion anisotropy. The other key data acquisition parameters for the diffusion scan were TR/TE ¼ 4000/97. 4 
Image Analysis and Therapeutic Response Assessment
According to the FROC model, the voxel intensity in a diffusion-weighted (DW) image is given by
where G d is the diffusion gradient amplitude, b (dimensionless; 0 b 1) is a fractional-order derivative that has been linked to intravoxel heterogeneity (20, 23, 24) , m (in units of mm) is a spatial constant to preserve the nominal units (mm 2 /s) of diffusion coefficient D (14, 20) , and d and D are defined previously.
The three parameters (D, b, and m) of the FROC model were fitted to the multiple b-value diffusion images, voxel by voxel, using a Levenberg-Marquardt nonlinear fitting algorithm (20, 27) . The initial value of D was determined from a mono-exponential function using the data acquired at low b-values ( 1000 s/mm 2 ), making it equivalent to ADC to facilitate comparison. After D was determined, b and m were obtained from fitting to Equation [1] with an initial value of 0.9 and 8 mm, respectively. A number of other initial b and m values were also investigated, and consistent fitting results were achieved regardless of the initial values. All image processing and analysis were performed using customized software developed in MATLAB (MathWorks Inc, Natick, MA). The computational time for FROC analysis was approximately 35 s/slice on a personal computer with a dual-core CPU (Intel Core i5; 3.30 GHz; 16 GB) on a Windows 7 operating system.
Aided by and confirmed with T 1 -and T 2 -weighted images, regions of interest (ROIs) outlining the solid portion of the lesions were placed on the DW images with b ¼ 1000 s/mm 2 . The largest area of the lesion was determined jointly by two senior radiologists (L.T. and Y.S.S., with 10 and 15 years of experience in clinical body MR, respectively), who were blinded to the knowledge of good versus poor responders determined by the modified Choi criteria for MRI (3) at the 12-week time point. Large areas of cystic or myxoid degeneration necrosis, if present on the pretreatment images, were excluded from the ROIs across all three time points. The means and standard deviations of D, b, and m were obtained in the ROIs. For comparison, the LD of the lesion was also measured on the T 2 -weighted images.
The mean values of the FROC parameters (D, b, and m) before treatment (X pre ) and 2 weeks after initiation of sunitinib therapy (X week2 ) were calculated over the selected tumor ROIs, and used to evaluate a percentage change (DX) as follows:
where X represents any of the three FROC parameters. Similarly, the changes in tumor size at 2 weeks (DLD) and 12 weeks (DLD week12 ) were also computed. We used the modified Choi criteria for MRI (3, 28) to determine the response of the tumors to sunitinib treatment at the 12-week time point, in which good responders were defined as lesions with at least 10% reduction in DLD week12 or displaying apparent cystic or myxoid degeneration (similar to HU decrease on CT) after 12 weeks of therapy, whereas the other lesions were classified as poor responders.
Statistical Analysis
All statistical analyses were performed using SPSS for Windows (Version 22.0, IBM Corp, Armonk, NY) with a statistical significance set at P < 0.05. First, the normality of the distributions of D, b, m, LD, DD, Db, Dm, and DLD were evaluated by a Kolmogorov-Smirnov test. All parameters were compared between the good responder and poor responder groups using a student's t-test for normal distribution or a Mann-Whitney U-test for nonnormal distribution. Using the modified Choi criteria for MRI with imaging data acquired at the 12-week time point as a standard of reference, receiver operating characteristic (ROC) analysis and the associated area under the ROC curve (AUC) were used to evaluate the performance for predicting the response to sunitinib therapy at the 2-week time point. Next, the FROC parameters immediately before sunitinib therapy (D pre , b pre , and m pre ) were used as a precondition in conjunction with DD in a pair-wise analysis, including (D pre , DD), (b pre , DD) and (m pre , DD), for predicting response at 2 weeks. The analysis was done using a binary logistic regression, which assumes that the probability of being a poor responder (denoted by P 0 ) follows the logistic model
where a 0 , a 1 , and a 2 are the regression coefficients that were estimated using a maximum likelihood method (29) . P 0 was then used in the ROC analysis, and its performance compared with that of using DD or DLD.
RESULTS
Lesion Characteristics
In the study, a total of 15 patients (age range: 25-78 years; median age: 60 years; 8 females, 7 males) was included, and one patient was excluded because of severe distortion artifacts on the diffusion images. Among the 15 patients included, a total of 80 target lesions were identified on the MR images. Six lesions were excluded because of artifacts on DW images or inconsistent appearance across all three time points, and the remaining 74 lesions were included in the analysis. There were four primary GIST lesions located at the gastrointestinal loci (stomach n ¼ 2; small bowel n ¼ 2) and 70 metastatic lesions in the mesentery/ peritoneum/omentum (n ¼ 45), liver (n ¼ 24), and kidney (n ¼ 1). According to the modified Choi criteria for MRI, 42 lesions responded well to sunitinib therapy, and 32 lesions poorly. Among the 15 patients, we observed two cases that had lesions with both good and poor responses in the same patient.
Representative FROC Maps change in tumor size at 2 weeks (LD ¼ 5.26 cm; Fig. 1ii ), but a substantial decrease after 12 weeks of sunitinib therapy (LD ¼ 3.78 cm; Fig. 1iii ). The DW images and the FROC maps before treatment (second row in Fig. 1 ) and 2 weeks after treatment (third row in Fig. 1 ) showed that D (0.74 versus 0.93 mm 2 /ms) and m (7.1 versus 7.6 mm) increased while b (0.69 versus 0.59) decreased. Figure 2 displays a set of images from a poor responding lesion (55-year-old female) whose size continued to increase from 2.75 cm pretreatment (Fig. 2i ) to 3.02 cm at 2 weeks (Fig.  2ii ) and 3.51 cm at 12 weeks (Fig. 2iii) . Unlike Figure 1 , the lesion in Figure 2 Fig. 2c ), suggesting that a precondition may be exploited in predicting the response.
Quantitative Comparison at the 2-Week Time Point
Quantitative comparisons of D, b, m, and LD between pretreatment and 2 weeks after treatment are provided in Table 1 . Our statistical analyses indicated that b pre and b week2 of the good responder group were significantly lower than those of the poor responder group (P ¼ 0.011 and 0.002, respectively), reinforcing the observation in Figures 1 and 2 . All other pretreatment metrics did not show significant difference. Two weeks after the sunitinib therapy, the median value of DD increased by 45.7% in the good responder group, as compared with only 12.4% in the poor responder group (Z ¼ À3.30, P ¼ 0.001; Fig. 3 ). No significant differences were observed in Db (Z ¼ À0.245, P ¼ 0.807), Dm (Z ¼ À1.724, P ¼ 0.085), or DLD (Z ¼ À1.517, P ¼ 0.129), as illustrated in Figure 3 .
The ROC Analysis
The AUC values from the ROC analysis on DD, Db, Dm, and DLD after 2 weeks of therapy are listed in Table 2 . Consistent with the results in Figure 3 , DD showed statistical significance (P ¼ 0.001) for predicting the response to sunitinib therapy, and improved the AUC from 0.580 to 0.725 when compared with the conventional criterion relying on DLD, which did not exhibit statistical significance (P ¼ 0.243). When DD was combined with any of the three pretreatment FROC parameters, the AUC was increased from using DD alone ( Table 2 ). The combination (b pre , DD) produced the largest AUC (0.843) and clearly outperformed either DD (AUC DD ¼ 0.725, Z ¼ 3.09, The metric with the highest AUC is highlighted in bold.
predicting the response at the 2-week time point, as demonstrated in Figure 4 . b pre was plotted against DD for all 74 lesions in Figure 5 , where the good responder and the poor responder groups were best separated by a line (4.3DD À 9.63b pre þ 5.98 ¼ 0) corresponding to a probability of P 0 ¼ 0.5 in the logistic model, in which b pre and DD were independent variables.
DISCUSSION
Accurately evaluating response to targeted therapy at the earliest time point is one of the most important aspects in treating unresectable GIST tumors. Using a nonGaussian FROC diffusion model, we have demonstrated that the combination of a pretreatment parameter b pre and a treatment-induced diffusion coefficient change DD can considerably improve the accuracy over the approach of using DD alone or relying on tumor-size change in predicting GIST response to second-line sunitinib therapy. More importantly, the present study has demonstrated the feasibility of predicting the response in as early as 2 weeks following the initiation of sunitinib treatment, a reduction of up to 10 weeks as compared with the conventional approach of measuring tumor-size change in 3 months, which is used by both response evaluation criteria in solid tumors and Choi criteria (28). These results enabled by a novel diffusion imaging method are significant, as earlier and more accurate prediction would allow the nonresponding GIST patients to timely switch to alternative therapies and minimize treatment toxicity. Previous studies have shown that change in ADC can be a sensitive and early marker for assessing GIST response to first-line imatinib treatment (3, (30) (31) (32) , consistent with a growing number of publications illustrating the role of ADC for monitoring cancer therapy (1, 2, 6, (33) (34) (35) (36) (37) . Among them, one study (3) demonstrated that ADC increases significantly after only 1 week of first-line imatinib treatment of GISTs in the good responders. A substantial increase in diffusion coefficient ($45.7%; Fig. 3 ) was also observed in our study in lesions responding favorably to the second-line sunitinib therapy. Interestingly, unlike the previous study (3) that reported no increase (or decrease) in ADC in poor responders to the first-line imatinib treatment, we observed a moderate increase in D ($12%; Fig. 3) among GISTs who responded poorly to the second-line sunitinib therapy, leading to a compromised performance of using DD alone to separate the good responder from poor responder groups (AUC ¼ 0.725; Fig. 4) .
The compromised performance of DD (or DADC) for predicting response to sunitinib therapy is likely caused by pre-existing conditions as a result of prior first-line treatment. Lesions undergone imatinib treatment can become heterogeneous even if they did not show significant reduction in size (3, 28) . The b parameter in the FROC diffusion model has been reported to be inversely related to the degree of intravoxel heterogeneity (14, 20, (23) (24) (25) 38) . Before the second-line sunitinib treatment, a significant difference in b value (i.e., b pre ) was observed between the good responder and poor responder groups (Table 1) , suggesting the existence of a possible precondition. This precondition was carried over throughout at least the first 2 weeks of sunitinib treatment, which explains the significant difference in b week2 that mirrors b pre (Table 1) , but no significant change in Db (Fig. 3 and Table 2 ).
By taking advantage of this precondition, the combination of b pre and DD produced the best performance with an AUC of 0.843 (Fig. 4 and Table 2 ) and a predictive accuracy of 75.7% (56 of 74). If a lesion is more heterogeneous before sunitinib treatment (i.e., lower b pre ), a smaller increase in D during treatment would indicate a good response. One possible explanation is that more heterogeneous lesions can be mixed with inactive regions such as cyst or necrosis, whose diffusion property does not change much during the course of treatment, resulting in an overall smaller change in D when these lesions respond to targeted therapy.
The precondition may also exist in D pre and m pre , as demonstrated in Table 2 . However, these preconditions were much weaker than b pre , which itself showed a moderate AUC value of 0.671 (data not included in Fig.  4 for simplicity). Any precondition reflected by D pre is likely related to tissue cellularity, but not to the degree of tissue heterogeneity in GIST following the first-line targeted therapy. According to the FROC model, m is strongly coupled with D (14, 20) , explaining the similar behavior between D and m observed in this study (Table  1) . One important exception is that DD showed a significant predictive power, whereas Dm did not (Fig. 3) .
The strong coupling between D and m was recognized at the beginning of FROC model development (14, 20) . Mathematically, these two parameters cannot be determined independently. Our strategy to solve this issue was to fit D by a mono-exponential function using low bvalues (b < 1000 s/mm 2 ) where the nominal diffusion process is dominant. After the diffusion coefficient was fixed, m and b were determined from a nonlinear fitting according to Equation [1] . This approach makes D equivalent to ADC, allowing the FROC model to be used without losing any potential benefits afforded by ADC. Additionally, this approach also allows exploring the potential role of m in microstructural characterization, as indicated in previous studies (14, 20) . An alternative way to decouple D and m is to fix m to a specific value, such as 1. Given the potential benefits of treating m as a variable, we did not explore this alternative strategy in this study.
The FROC model represents a special case of a more generalized continuous-time random-walk model that recognizes intravoxel diffusion heterogeneity in both time (denoted by a) and space (denoted by b) (17) . To accurately estimate a, diffusion measurements need to be performed by varying not only diffusion gradient amplitude, but also the diffusion time D. In a clinical setting, this can be rather difficult to implement, constrained by the echo time to preserve the signal-to-noise ratio, the total scan time, and the limited gradient strength on a clinical scanner (e.g., 50-80 mT/m). In addition, nonlinear fitting to determine the parameters in the continuous-time random-walk model has been shown to be more sensitive to noise in the image as compared with the FROC model. For these reasons, our study was limited to the FROC model by assuming a ¼ 1.
Another limitation of this pilot study is the small number of patients. Although we analyzed multiple lesions from several patients and observed that lesions in the same patient could have differing responses, in general lesions from the same patient tend to react to targeted therapy in the same way. Thus, treating multiple lesions from the same patient as independent samples has only a moderate effect on improving the statistical power. Additionally, we used modified Choi criteria for MRI at 12 weeks as a "gold standard" to determine good versus poor responders in this pilot study. The applicability of this standard in the context of second-line sunitinib therapy may require validation by a correlation with long-term prognosis such as progression-free survival and the overall survival.
In conclusion, our study has demonstrated that changes in diffusion coefficient can be a predictive indicator for early response to second-line sunitinib therapy of GIST. More importantly, the change in diffusion coefficient during treatment can be combined with a tissue heterogeneity parameter b before treatment, to considerably improve prediction of good versus poor responders only 2 weeks after initiating the treatment, yielding an AUC of 0.843 and an accuracy of 75.7% (56 of 74). These results indicate that high b-value diffusion imaging with a non-Gaussian FROC model has the potential of predicting the response of GIST to second-line Sunitinib targeted therapy earlier (e.g., 2 weeks) than the present approach, and more accurately than using ADC alone.
